
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer
WILMINGTON, DE — Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when followed by paclitaxel, trastuzumab, and pertuzumab (THP), significantly improved pathologic complete response (pCR) …
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer Read More